The KMO inhibitors, such as Ro61-8048, have been reported to decrease dyskinesia induced by L-DOPA in monkeys administered with MPTP, with no comprise in the therapeutic role of L-DOPA, as well as elevated production of KYNA [102,179]. Here, KMO is linked to drug-induced dyskinesia.